Skip to main content

Advertisement

Log in

Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The aim of this study was to evaluate the efficacy and toxicities of second-line chemotherapy regimens with docetaxel and gemcitabine (GD), or paclitaxel and gemcitabine (GP) for advanced or metastatic urothelial carcinoma (UC) that did not respond to first-line platinum-based chemotherapy.

Methods

From 2002 to 2017, 78 patients with metastatic UCs that progressed after platinum-based chemotherapy were treated with either GD (n = 41) or GP (n = 37). We compared these two different regimens by analyzing their efficacy and toxicities in a retrospective manner.

Results

Of the 78 patients enrolled in this study, it was possible to determine treatment efficacy in 70; the proportion of patients with objective response and disease control were 8.6 (9/70) and 54.3% (38/70), respectively. The median progression-free survival and overall survival in the total population (GP and GD) were 3.5 (95% CI 0.6–53.3) and 9.6 months (95% CI 1.2–53.3), respectively. There was no significant difference between the two regimens (GD or GP) regarding survival outcomes. Treatment-related adverse events were mostly manageable, but one patient died as a result of febrile neutropenia. The presence of liver metastasis and anemia (Hb < 10.0 g/dl) was prognostic factors for worse survival.

Conclusions

Combination chemotherapy with either GP or GD was a favorable and well-tolerated second-line treatment regimen for patients with advanced or metastatic UC following the failure of a platinum-based regimen. Further study using a large prospective cohort is needed to identify patients who will benefit from second-line combination therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Logothetis CJ, Dexeus FH, Finn L et al. (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8(6):1050–1055. https://doi.org/10.1200/JCO.1990.8.6.1050

    Article  CAS  PubMed  Google Scholar 

  2. Saxman SB, Propert KJ, Einhorn LH et al. (1997) Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 15(7):2564–2569. https://doi.org/10.1200/JCO.1997.15.7.2564

    Article  CAS  PubMed  Google Scholar 

  3. von der Maase H, Hansen SW, Roberts JT et al. (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18(17):3068–3077. https://doi.org/10.1200/JCO.2000.18.17.3068

    Article  PubMed  Google Scholar 

  4. von der Maase H, Sengelov L, Roberts JT et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23(21):4602–4608. https://doi.org/10.1200/JCO.2005.07.757

    Article  CAS  PubMed  Google Scholar 

  5. Ortmann CA, Mazhar D (2013) Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. Future Oncol 9(11):1637–1651. https://doi.org/10.2217/fon.13.139

    Article  CAS  PubMed  Google Scholar 

  6. Bellmunt J, de Wit R, Vaughn DJ et al. (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/NEJMoa1613683

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Dreicer R, Manola J, Schneider DJ et al. (2003) Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 97(11):2743–2747. https://doi.org/10.1002/cncr.11413

    Article  CAS  PubMed  Google Scholar 

  8. Albers P, Park SI, Niegisch G et al. (2011) Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 22(2):288–294. https://doi.org/10.1093/annonc/mdq398

    Article  CAS  PubMed  Google Scholar 

  9. Kobayashi K, Matsuyama H, Shimizu K et al. (2016) Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy. Jpn J Clin Oncol 46(8):775–780. https://doi.org/10.1093/jjco/hyw071

    Article  PubMed  Google Scholar 

  10. Bellmunt J, Fougeray R, Rosenberg JE et al. (2013) Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 24(6):1466–1472. https://doi.org/10.1093/annonc/mdt007

    Article  CAS  PubMed  Google Scholar 

  11. Sideris S, Aoun F, Zanaty M et al. (2016) Efficacy of weekly paclitaxel treatment as a single agent chemotherapy following first-line cisplatin treatment in urothelial bladder cancer. Mol Clin Oncol 4(6):1063–1067. https://doi.org/10.3892/mco.2016.821

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Sonpavde G, Pond GR, Choueiri TK et al. (2016) Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial carcinoma. Eur Urol 69(4):634–641. https://doi.org/10.1016/j.eururo.2015.07.042

    Article  CAS  PubMed  Google Scholar 

  13. Raggi D, Miceli R, Sonpavde G et al. (2016) Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann Oncol 27(1):49–61. https://doi.org/10.1093/annonc/mdv509

    Article  CAS  PubMed  Google Scholar 

  14. Naiki T, Kawai N, Hashimoto Y et al. (2014) Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma. Int J Clin Oncol 19(3):516–522. https://doi.org/10.1007/s10147-013-0574-1

    Article  CAS  PubMed  Google Scholar 

  15. Sonpavde G, Pond GR, Fougeray R et al. (2013) Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol 63(4):717–723. https://doi.org/10.1016/j.eururo.2012.11.042

    Article  PubMed  Google Scholar 

  16. Bellmunt J, Choueiri TK, Fougeray R et al. (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850–1855. https://doi.org/10.1200/JCO.2009.25.4599

    Article  PubMed  Google Scholar 

  17. Sternberg CN, Calabro F, Pizzocaro G et al. (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92(12):2993–2998

    Article  CAS  PubMed  Google Scholar 

  18. Meluch AA, Greco FA, Burris HA et al. (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 19(12):3018–3024. https://doi.org/10.1200/JCO.2001.19.12.3018

    Article  CAS  PubMed  Google Scholar 

  19. Kaufman DS, Carducci MA, Kuzel TM et al. (2004) A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 22(5):393–397. https://doi.org/10.1016/j.urolonc.2004.01.002

    Article  CAS  PubMed  Google Scholar 

  20. Li J, Juliar B, Yiannoutsos C et al. (2005) Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 23(6):1185–1191. https://doi.org/10.1200/JCO.2005.05.089

    Article  CAS  PubMed  Google Scholar 

  21. Fechner G, Siener R, Reimann M et al. (2006) Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract 60(1):27–31. https://doi.org/10.1111/j.1742-1241.2005.00663.x

    Article  CAS  PubMed  Google Scholar 

  22. McCaffrey JA, Hilton S, Mazumdar M et al. (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15(5):1853–1857. https://doi.org/10.1200/JCO.1997.15.5.1853

    Article  CAS  PubMed  Google Scholar 

  23. Kim YS, Lee SI, Park SH et al. (2016) A phase II study of weekly docetaxel as second-line chemotherapy in patients with metastatic urothelial carcinoma. Clin Genitourin Cancer 14(1):76–81. https://doi.org/10.1016/j.clgc.2015.09.008

    Article  PubMed  Google Scholar 

  24. Gitlitz BJ, Baker C, Chapman Y et al. (2003) A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Cancer 98(9):1863–1869. https://doi.org/10.1002/cncr.11726

    Article  CAS  PubMed  Google Scholar 

  25. Kakutani S, Fukuhara H, Taguchi S et al. (2015) Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma. Jpn J Clin Oncol 45(3):281–285. https://doi.org/10.1093/jjco/hyu201

    Article  PubMed  Google Scholar 

  26. Petrylak DP, de Wit R, Chi KN et al. (2017) Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet 390(10109):2266–2277. https://doi.org/10.1016/S0140-6736(17)32365-6

    Article  CAS  PubMed  Google Scholar 

  27. Yuasa T, Urakami S, Yonese J (2018) Recent advances in medical therapy for metastatic urothelial cancer. Int J Clin Oncol. https://doi.org/10.1007/s10147-018-1260-0

    Article  PubMed  PubMed Central  Google Scholar 

  28. Suyama T, Ueda T, Fukasawa S et al. (2009) Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol 39(4):244–250. https://doi.org/10.1093/jjco/hyp003

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Minoru Kato.

Ethics declarations

Compliance with ethical standards

Conflict of interest

All authors declared that they have no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLSX 10 KB)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Takeyama, Y., Kato, M., Nishihara, C. et al. Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma. Int J Clin Oncol 23, 944–950 (2018). https://doi.org/10.1007/s10147-018-1288-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-018-1288-1

Keywords

Navigation